SGLT2 inhibitors, GLP-1RAs, MRBs show emerging cardiorenal protection in Type 1 Diabetes.
Background
Individuals with Type 1 Diabetes (T1D) face a significantly doubled risk of cardiovascular disease (CVD) and chronic kidney disease (CKD) compared to healthy individuals, even with stringent glycemic management. Historically, therapeutic strategies specifically targeting cardiorenal risk reduction in this population have been limited. While Type 2 Diabetes (T2D) treatment has been revolutionized by drugs offering substantial cardiorenal protection, T1D patients were largely excluded from these trials, creating a critical unmet need for effective cardiorenal protective agents.
Study Design
This review article synthesizes current evidence on the high risk of cardiovascular disease (CVD), heart failure (HF), and chronic kidney disease (CKD) in Type 1 Diabetes (T1D). It specifically discusses emerging data for cardiorenal protection offered by sodium-glucose cotransporter inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and mineralocorticoid receptor blockers (MRBs) in T1D patients, drawing from recent trials that included this population.
Results
The review highlights that individuals with Type 1 Diabetes (T1D) face a significantly elevated risk of cardiovascular disease (CVD), heart failure (HF), and chronic kidney disease (CKD). It compiles evidence demonstrating that sodium-glucose cotransporter inhibitors (SGLT2i), previously primarily studied in Type 2 Diabetes (T2D), now show promise in T1D for reducing major adverse cardiovascular events (MACE) and slowing CKD progression. Similarly, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are identified as offering significant cardiovascular benefits, including reductions in atherosclerotic CVD and HF hospitalization. > Mineralocorticoid receptor blockers (MRBs) are also presented as a crucial class for mitigating renal disease progression and cardiovascular risk in T1D, particularly in patients with albuminuria. These agents collectively represent a paradigm shift, moving beyond glycemic control to provide comprehensive cardiorenal protection for T1D patients.
Why It Matters
This review marks a significant shift in the management paradigm for Type 1 Diabetes (T1D), emphasizing the importance of cardiorenal protection beyond glycemic control. Clinicians should now actively consider integrating SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor blockers into T1D treatment protocols for their proven benefits in reducing cardiovascular disease (CVD), heart failure (HF), and chronic kidney disease (CKD) risk. This expands the therapeutic arsenal for T1D patients, offering a more holistic approach to long-term health and potentially improving quality of life and longevity by mitigating severe complications.